# A Phase 1 Multiple Dose Study to Compare the Effects of AMG 223 and Sevelamer HCL (Renagel®)

> **NCT00756860** · PHASE1 · COMPLETED · sponsor: **Amgen Research (Munich) GmbH** · enrollment: 66 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** AMG 223
- **DRUG:** Renagel® (sevelamer hydrochloride)

## Key facts

- **NCT ID:** NCT00756860
- **Lead sponsor:** Amgen Research (Munich) GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2008-08
- **Final completion:** 2009-09
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2012-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00756860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00756860, "A Phase 1 Multiple Dose Study to Compare the Effects of AMG 223 and Sevelamer HCL (Renagel®)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00756860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*